What is the role of EC-MPS in immunosuppression after solid organ transplantation?

Updated: Jan 04, 2016
  • Author: Bethany Pellegrino, MD; Chief Editor: Mary C Mancini, MD, PhD, MMM  more...
  • Print


Enteric-coated mycophenolate sodium (EC-MPS)

EC-MPS is introduced with fewer reports of gastrointestinal adverse effects. Acute noninfectious diarrhea after simultaneous pancreas and kidney transplantation is related to the duration of diabetes and to prescription of mycophenolate mofetil, a prodrug of mycophenolate acid. Preferential use of EC-MPS is associated with a lower necessity of dose reduction and less severe episodes of acute diarrhea compared with mycophenolate mofetil, although dose reduction is equally associated with acute episodes of kidney rejection.

Clinical trials, including the Myfortic Prospective Multicenter Study (myPROMS), have begun to demonstrate similar clinical outcomes (eg, rejection rates) between the 2 drugs.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!